Jazz Pharmaceuticals plc (NASDAQ:JAZZ) CEO Bruce C. Cozadd Sells 500 Shares

Jazz Pharmaceuticals plc (NASDAQ:JAZZ - Get Free Report) CEO Bruce C. Cozadd sold 500 shares of the business's stock in a transaction dated Monday, June 2nd. The stock was sold at an average price of $107.90, for a total value of $53,950.00. Following the transaction, the chief executive officer now directly owns 438,473 shares of the company's stock, valued at $47,311,236.70. The trade was a 0.11% decrease in their position. The sale was disclosed in a filing with the SEC, which is available through this hyperlink.

Jazz Pharmaceuticals Stock Up 2.1%

Shares of NASDAQ JAZZ traded up $2.33 during trading on Friday, reaching $111.13. The company had a trading volume of 726,472 shares, compared to its average volume of 836,816. The company has a quick ratio of 3.74, a current ratio of 4.26 and a debt-to-equity ratio of 1.46. Jazz Pharmaceuticals plc has a 12-month low of $95.49 and a 12-month high of $148.06. The stock has a market cap of $6.85 billion, a PE ratio of 15.65, a P/E/G ratio of 1.04 and a beta of 0.33. The business's 50-day moving average is $108.09 and its 200 day moving average is $120.98.

Jazz Pharmaceuticals (NASDAQ:JAZZ - Get Free Report) last announced its earnings results on Tuesday, May 6th. The specialty pharmaceutical company reported $1.68 earnings per share (EPS) for the quarter, missing the consensus estimate of $4.65 by ($2.97). The firm had revenue of $897.84 million during the quarter, compared to analysts' expectations of $984.16 million. Jazz Pharmaceuticals had a return on equity of 29.30% and a net margin of 11.60%. The company's revenue for the quarter was down .5% on a year-over-year basis. During the same period in the previous year, the business posted $2.68 earnings per share. As a group, equities analysts forecast that Jazz Pharmaceuticals plc will post 16.96 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

JAZZ has been the subject of several recent analyst reports. Robert W. Baird cut their price objective on Jazz Pharmaceuticals from $167.00 to $155.00 and set an "outperform" rating for the company in a report on Wednesday, May 7th. Barclays reaffirmed an "overweight" rating and issued a $200.00 target price (up previously from $190.00) on shares of Jazz Pharmaceuticals in a research note on Thursday, February 27th. JPMorgan Chase & Co. upped their target price on Jazz Pharmaceuticals from $200.00 to $209.00 and gave the stock an "overweight" rating in a research note on Wednesday, February 26th. HC Wainwright upped their target price on Jazz Pharmaceuticals from $200.00 to $217.00 and gave the stock a "buy" rating in a research note on Monday, March 10th. Finally, Truist Financial upped their target price on Jazz Pharmaceuticals from $220.00 to $230.00 and gave the stock a "buy" rating in a research note on Thursday, March 6th. Two investment analysts have rated the stock with a hold rating and twelve have issued a buy rating to the company. Based on data from MarketBeat, Jazz Pharmaceuticals has a consensus rating of "Moderate Buy" and an average price target of $184.00.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently bought and sold shares of JAZZ. IFP Advisors Inc bought a new position in shares of Jazz Pharmaceuticals in the fourth quarter worth about $25,000. Quadrant Capital Group LLC raised its stake in Jazz Pharmaceuticals by 97.1% during the 4th quarter. Quadrant Capital Group LLC now owns 205 shares of the specialty pharmaceutical company's stock valued at $25,000 after purchasing an additional 101 shares during the period. Hurley Capital LLC bought a new stake in Jazz Pharmaceuticals in the 1st quarter worth approximately $25,000. Elequin Capital LP increased its stake in Jazz Pharmaceuticals by 677.8% in the 4th quarter. Elequin Capital LP now owns 210 shares of the specialty pharmaceutical company's stock worth $26,000 after acquiring an additional 183 shares during the last quarter. Finally, CoreFirst Bank & Trust purchased a new position in shares of Jazz Pharmaceuticals in the 4th quarter worth approximately $28,000. 89.14% of the stock is owned by hedge funds and other institutional investors.

About Jazz Pharmaceuticals

Jazz Pharmaceuticals plc identifies, develops, and commercializes pharmaceutical products for unmet medical needs in the United States, Europe, and internationally. The company offers Xywav for cataplexy or excessive daytime sleepiness (EDS) with narcolepsy and idiopathic hypersomnia; Xyrem to treat cataplexy or EDS with narcolepsy; Epidiolex for seizures associated with Lennox-Gastaut and Dravet syndromes, or tuberous sclerosis complex; Zepzelca to treat metastatic small cell lung cancer, or with disease progression on or after platinum-based chemotherapy; Rylaze for acute lymphoblastic leukemia or lymphoblastic lymphoma; Enrylaze to treat acute lymphoblastic leukemia and lymphoblastic lymphoma; Defitelio to treat severe hepatic veno-occlusive disease; and Vyxeos for newly-diagnosed therapy-related acute myeloid leukemia.